Literature DB >> 25514385

Characterization of clinical and immunological parameters during Ebola virus infection of rhesus macaques.

Karen Martins1, Christopher Cooper, Travis Warren, Jay Wells, Todd Bell, Jolynne Raymond, Kelly Stuthman, Jacqueline Benko, Nicole Garza, Sean van Tongeren, Ginger Donnelly, Cary Retterer, Lian Dong, Sina Bavari.   

Abstract

The rhesus macaque serves as an animal model for Ebola virus (EBOV) infection. A thorough understanding of EBOV infection in this species would aid in further development of filovirus therapeutics and vaccines. In this study, pathological and immunological data from EBOV-infected rhesus macaques are presented. Changes in blood chemistries, hematology, coagulation, and immune parameters during infection, which were consistently observed in the animals, are presented. In an animal that survived challenge, a delay was observed in the detection of viral RNA and inflammatory cytokines and chemokines which may have contributed to survival. Collectively, these data add to the body of knowledge regarding EBOV pathogenesis in rhesus macaques and emphasize the reproducibility of the rhesus macaque challenge model.

Entities:  

Mesh:

Year:  2015        PMID: 25514385     DOI: 10.1089/vim.2014.0085

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  19 in total

Review 1.  Animal Models of Ebolavirus Infection.

Authors:  Marisa C St Claire; Dan R Ragland; Laura Bollinger; Peter B Jahrling
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

2.  Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.

Authors:  Judith Olejnik; Adriana Forero; Laure R Deflubé; Adam J Hume; Whitney A Manhart; Andrew Nishida; Andrea Marzi; Michael G Katze; Hideki Ebihara; Angela L Rasmussen; Elke Mühlberger
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

Review 3.  Filovirus Strategies to Escape Antiviral Responses.

Authors:  Judith Olejnik; Adam J Hume; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler; Elke Mühlberger
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

4.  Adipocytes are susceptible to Ebola Virus infection.

Authors:  Francoise A Gourronc; Michael R Rebagliati; Breanna Kramer-Riesberg; Anthony M Fleck; J J Patten; Kathleen Geohegan-Barek; Kelly N Messingham; Robert A Davey; Wendy Maury; Aloysius J Klingelhutz
Journal:  Virology       Date:  2022-05-27       Impact factor: 3.513

5.  Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.

Authors:  Andrea Marzi; Patrick W Hanley; Elaine Haddock; Cynthia Martellaro; Gary Kobinger; Heinz Feldmann
Journal:  J Infect Dis       Date:  2016-08-05       Impact factor: 5.226

Review 6.  Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.

Authors:  Azizul Haque; Didier Hober; Joel Blondiaux
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

7.  Delayed Disease Progression in Cynomolgus Macaques Infected with Ebola Virus Makona Strain.

Authors:  Andrea Marzi; Friederike Feldmann; Patrick W Hanley; Dana P Scott; Stephan Günther; Heinz Feldmann
Journal:  Emerg Infect Dis       Date:  2015-10       Impact factor: 6.883

Review 8.  Molecular mechanisms of Ebola virus pathogenesis: focus on cell death.

Authors:  L Falasca; C Agrati; N Petrosillo; A Di Caro; M R Capobianchi; G Ippolito; M Piacentini
Journal:  Cell Death Differ       Date:  2015-05-29       Impact factor: 15.828

9.  Circulating microRNA profiles of Ebola virus infection.

Authors:  Janice Duy; Jeffrey W Koehler; Anna N Honko; Randal J Schoepp; Nadia Wauquier; Jean-Paul Gonzalez; M Louise Pitt; Eric M Mucker; Joshua C Johnson; Aileen O'Hearn; James Bangura; Moinya Coomber; Timothy D Minogue
Journal:  Sci Rep       Date:  2016-04-21       Impact factor: 4.379

10.  Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial.

Authors:  Jake Dunning; Foday Sahr; Amanda Rojek; Fiona Gannon; Gail Carson; Baimba Idriss; Thomas Massaquoi; Regina Gandi; Sebatu Joseph; Hassan K Osman; Timothy J G Brooks; Andrew J H Simpson; Ian Goodfellow; Lucy Thorne; Armando Arias; Laura Merson; Lyndsey Castle; Rebecca Howell-Jones; Raul Pardinaz-Solis; Benjamin Hope-Gill; Mauricio Ferri; Jennifer Grove; Mark Kowalski; Kasia Stepniewska; Trudie Lang; John Whitehead; Piero Olliaro; Mohammed Samai; Peter W Horby
Journal:  PLoS Med       Date:  2016-04-19       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.